Lirafugratinib FDA Approval: Best-in-Class ORR Signal, But Third-Entrant HTA Trap Looms

FDA Approves Elevar's Lyrfigtu for FGFR2-Altered Cholangiocarcinoma

Elevar Therapeutics announced that the U.S. FDA has approved LYRFIGTU (lirafugratinib) as a second-line treatment for patients with cholangiocarcinoma (CCA) harboring FGFR2 fusion or other rearrangement. This approval is based on data from the Phase 1/2 ReFocus trial (NCT04526106), where Lyrfigtu demonstrated a confirmed objective response rate (ORR) of 46% and a median duration of response (mDOR) of 11.8 months. The drug is expected to be available in the U.S. by Q4 2026, offering a new precision medicine option for this rare bile duct cancer, which affects approximately 8,000 people annually in the U.S.

• In the Phase 1/2 ReFocus trial, Lyrfigtu achieved a confirmed objective response rate (ORR) of 46% and a median duration of response (mDOR) of 11.8 months in patients with FGFR2-altered cholangiocarcinoma. Additionally, the median progression-free survival (PFS) was 11.3 months (95% CI, 9.2, 14.8), with a 12-month PFS rate of 49.2%, demonstrating robust and durable treatment responses.
• Lyrfigtu is an irreversible, covalent-binding FGFR2 inhibitor that selectively targets FGFR2, including many resistance mutations, while minimizing off-isoform toxicities. This unique mechanism provides potent and sustained inhibition, distinguishing it from earlier pan-FGFR inhibitors and offering a next-generation precision medicine approach for advanced bile duct cancer.
• The clinical data showed Lyrfigtu to have a predictable and manageable safety profile, with adverse reactions often managed through dose adjustments. Common adverse reactions included ocular toxicity (RPED, blurred vision, dry eye), hyperphosphatemia, and nail toxicity. This manageable profile, combined with deep and durable responses, has allowed patients to regain meaningful quality of life.
• The FDA granted Lyrfigtu Priority Review designation in March 2026, underscoring its potential for significant improvements in treatment. Its approval introduces a vital second-line option for patients with limited therapeutic choices, reinforcing the importance of molecular testing. Lyrfigtu is anticipated to be commercially available in the U.S. by Q4 2026.

Addressing Key Challenges in FGFR2-Altered CCA Treatment

Despite meaningful clinical advances with selective FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma, durable disease control remains elusive. Virtually all patients who respond to initial FGFR inhibitor therapy eventually develop acquired resistance, driving an urgent need for next-generation therapeutic strategies.

• Polyclonal on-target FGFR2 kinase domain mutations dominate the resistance landscape in CCA. At progression on both reversible inhibitors (e.g., pemigatinib, erdafitinib) and the irreversible inhibitor futibatinib, polyclonal FGFR2 kinase domain mutations were frequent in cholangiocarcinoma (14/27 patients), affecting key residues including the gatekeeper (V565), molecular brake residues (N550, E566, K642), and others. After futibatinib, resistance was narrowed to mutations at N550 and V565 only, with the V565L/F/Y variants proving particularly recalcitrant.

• Off-target resistance mechanisms — particularly in the MAPK and PI3K/AKT/mTOR pathways — compound the challenge. Off-target alterations in PI3K/mTOR and MAPK pathways were identified in 11 patients, frequently co-occurring with on-target FGFR2 mutations. Convergent genomic evolution in the MAPK pathway — including emergence of BRAF V600E, NRAS Q61K, NRAS G12C, NRAS G13D, and KRAS G12K mutations upon progression — has been documented in serially collected plasma samples. In vitro, concomitant KRAS G12D or BRAF V600E conferred resistance to FGFR inhibition, and in vivo combination of MEK inhibition with FGFR inhibition was not able to overcome KRAS-mediated resistance.

• Post-progression treatment options are limited and outcomes remain poor. Following cessation of first FGFR inhibitor therapy, median PFS on chemotherapy or targeted agents was 2.1 months (95% CI 1.6–5.7) and 3.7 months (95% CI 1.5–not evaluable) on a second FGFR inhibitor. OS was 2.0 months for patients who received no further therapy. Nearly half of patients become ineligible for further systemic therapy after progression on an FGFR inhibitor.

• Ocular and other class-related toxicities constrain dosing and continuity of treatment. Serous retinal detachment (SRD) has been observed with pemigatinib and requires dose interruption and reduction — from 13.5 mg to 9 mg and further to 4.5 mg in documented cases. With infigratinib, central serous retinopathy-like and retinal pigment epithelial detachment-like events occurred in 18 (17%) of patients. Hyperphosphatemia is an important risk shared across the class. These toxicities necessitate careful management to maintain therapeutic exposure.

• High intra- and interpatient molecular heterogeneity limits the generalizability of resistance-directed strategies. Polyclonality at resistance is a defining feature of CCA specifically — in contrast to other FGFR2-driven tumor types where polyclonal resistance was rare (1/9 patients). This heterogeneity, captured noninvasively via circulating tumor DNA liquid biopsies, reflects temporal evolution under selective pressure and complicates the design of uniform second-line approaches.

Lyrfigtu's Efficacy and Safety Profile in ReFocus Trial

Several recent clinical studies have evaluated FGFR inhibitors in patients with advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements, spanning phase 2 and phase 3 designs across second-line and first-line settings. The data collectively demonstrate meaningful objective response rates and manageable, class-consistent safety profiles across trials.

Evolving Treatment Landscape for FGFR2-Altered CCA

FGFR2 fusions or rearrangements occur in approximately 10–16% of intrahepatic cholangiocarcinoma (iCCA) cases, defining a molecularly distinct subtype with meaningful sensitivity to FGFR-targeted therapies. The approval of pemigatinib — a selective, potent, oral inhibitor of FGFR1–3 — marked the first regulatory recognition of FGFR inhibition in this setting, initially based on the phase 2 FIGHT-202 trial in previously treated patients. The subsequent phase 3 FIGHT-302 trial (NCT03656536) randomized adults with advanced FGFR2-rearranged cholangiocarcinoma 1:1 to first-line pemigatinib (13.5 mg once daily) versus gemcitabine plus cisplatin chemotherapy. Pemigatinib demonstrated a median progression-free survival of 8.3 months versus 6.8 months for chemotherapy (hazard ratio [95% CI], 0.58 [0.39–0.87]; nominal P=0.0078), an objective response rate of 47% versus 15%, and a median duration of response of 14.2 versus 6.3 months, establishing a first-line role for FGFR inhibition in this population. Futibatinib, a next-generation, covalently binding, irreversible FGFR1–4 inhibitor, further advanced the landscape through the phase 2 FOENIX-CCA2 study (NCT02052778), in which 103 patients with unresectable or metastatic FGFR2 fusion- or rearrangement-positive iCCA who had progressed on one or more prior lines of systemic therapy received oral futibatinib 20 mg once daily. A total of 43 of 103 patients (42%; 95% CI, 32–52) achieved an objective response, with a median duration of response of 9.7 months, median progression-free survival of 9.0 months, and median overall survival of 21.7 months at a median follow-up of 17.1 months.

A critical distinction shaping the current treatment paradigm is the mechanistic difference between reversible and irreversible FGFR inhibitors. Acquired resistance to earlier ATP-competitive (reversible) agents — most commonly driven by secondary kinase-domain mutations and activation of bypass signaling pathways — has emerged as a major limitation to sustained benefit. Futibatinib's covalent binding mechanism maintains inhibitory activity against a broad spectrum of FGFR2 resistance mutations, providing a strong biological rationale for its use following progression on reversible inhibitors. Real-world outcomes data from a multicentric retrospective analysis of 88 FGFR-altered CCA patients confirmed the challenge of post-FGFRi management: median PFS on initial FGFRi was 6.6 months, and among patients who received a second FGFRi after progression, median PFS was 3.7 months (95% CI, 1.5–not evaluable), compared with 2.1 months (95% CI, 1.6–5.7) for chemotherapy or other targeted agents. Notably, almost half of patients became ineligible for further systemic therapy following progression on FGFRi. Emerging agents such as tinengotinib — a spectrum-selective multi-kinase inhibitor targeting FGFR1–3, JAK1/2, VEGFRs, and Aurora A/B kinases — have shown particular promise in this resistant setting, achieving an ORR of 66.7% as monotherapy in cholangiocarcinoma harboring FGFR2 fusion progressing on prior FGFR inhibitor in a phase Ib/II trial (NCT05253053).

The safety and tolerability profiles of approved FGFR inhibitors have been characterized in increasing depth, informing clinical management strategies. A pooled safety analysis of 469 patients across three global phase I or II futibatinib studies identified hyperphosphatemia (82% any grade; 19% grade ≥3), nail disorders (27%/1%), hepatic adverse events (27%/11%), stomatitis (19%/3%), and palmar-plantar erythrodysesthesia syndrome (13%/3%) as the principal adverse events of clinical interest; discontinuations due to treatment-related adverse events were rare at 2%, and no treatment-related deaths occurred. A systematic review of pemigatinib, futibatinib, and ivosidenib similarly identified hyperphosphatemia, hypophosphatemia, and ocular disorders as class effects of FGFR inhibitors, all effectively managed through dose adjustments. Alongside these clinical advances, the growing role of circulating tumor DNA as a noninvasive tool for longitudinal molecular monitoring — and the identification of acquired resistance mechanisms such as PIK3CA gain-of-function mutations and homozygous CDKN2A/B deletions — are increasingly informing sequential treatment strategies and the rational design of combination approaches in FGFR2-altered biliary tract cancer.

Precision Redefined: Lirafugratinib's Impact on FGFR2-Altered CCA

The recent FDA approval of lirafugratinib for second-line FGFR2-altered cholangiocarcinoma represents a pivotal moment for patients battling this rare and aggressive cancer. This new therapeutic option, a highly selective and irreversible FGFR2 inhibitor, is designed to overcome some of the key limitations of earlier pan-FGFR inhibitors. By specifically targeting FGFR2 while sparing FGFR1 and FGFR4, lirafugratinib aims to significantly reduce common, dose-limiting toxicities such as hyperphosphatemia and diarrhea, which have historically impacted patient quality of life and treatment adherence.

The clinical data supporting this approval, including an objective response rate of 46% and a median duration of response of 11.8 months, suggest a meaningful improvement in outcomes for patients who have progressed on initial therapies. This efficacy, coupled with a potentially more favorable safety profile, positions lirafugratinib as a strong contender in the evolving landscape of targeted CCA treatments.

However, the journey for FGFR-targeted therapies is complex. While lirafugratinib shows promise against certain FGFR2 kinase domain mutations that confer resistance to other inhibitors, studies indicate that new resistance mechanisms, including novel FGFR2 mutations and RTK-MAPK bypass alterations, can still emerge. This underscores the ongoing need for comprehensive molecular profiling and the development of sequential or combination strategies to sustain therapeutic benefit. Furthermore, the commercialization of therapies for rare diseases like FGFR2-altered CCA presents inherent challenges, as evidenced by the early termination of previous confirmatory trials due to low patient accrual. Successfully navigating this competitive market will require robust real-world evidence and strategic differentiation to ensure this innovative therapy reaches the patients who need it most, ultimately optimizing targeted therapy in this biologically heterogeneous malignancy.